Trinity Biotech traded at $0.78 this Tuesday February 3rd, decreasing $0.04 or 4.76 percent since the previous trading session. Looking back, over the last four weeks, Trinity Biotech lost 2.15 percent. Over the last 12 months, its price fell by 15.68 percent. Looking ahead, we forecast Trinity Biotech to be priced at 0.79 by the end of this quarter and at 0.72 in one year, according to Trading Economics global macro models projections and analysts expectations.
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.